Menu Contact Dictionary Search. Understanding Cancer. What Is Cancer? Cancer Statistics.
What to know about HER2-negative breast cancer
Breast Cancer Hormone Receptor Status | Estrogen Receptor
When NCI-supported researchers discovered that the HER2 gene is important for breast cancer growth, this led to the development of the drug trastuzumab and other targeted treatments that have improved survival for women with HER2-positive breast cancer. For years, doctors and researchers have noted that not all cancers are alike. But for other patients, their tumors grow rapidly and spread like wildfire. In the early s, after the discovery that a mutated gene called HER2 could stimulate excessive cell growth and division, many scientists wondered if certain genes might make cancers grow and spread rapidly. Researchers around the world began searching for genes that spur cancer growth.
Breast Cancer HER2 Status
Triple negative is sometimes used as a surrogate term for basal-like ; however, more detailed classification may provide better guidance for treatment and better estimates for prognosis. Triple-negative breast cancers comprise a very heterogeneous group of cancers. There is conflicting information over prognosis for the various subtypes, but it appears that the Nottingham prognostic index is valid and hence general prognosis is rather similar with other breast cancer of same stage, except that more aggressive treatment is required. Triple-negative breast cancers have a relapse pattern that is very different from hormone-positive breast cancers: the risk of relapse is much higher for the first 3—5 years, but drops sharply and substantially below that of hormone-positive breast cancers afterwards.
Questions about the survival rate and recurrence rate are very common when someone is diagnosed with triple-negative breast cancer TNBC. While prognosis is, on average, poorer than with hormone receptor or human epidermal growth factor receptor 2 HER2 positive tumors, triple-negative breast cancer is a very heterogeneous diverse disease. On a positive note, and unlike hormone-positive tumors that commonly recur late after five years , late recurrence is less common with triple-negative tumors.